Medios AG has announced the closure of its Aschaffenburg facility, a wholly owned subsidiary of Medios Solutions Aschaffenburg GmbH, as part of an initiative to optimize its manufacturing network across Germany. The company is consolidating patient-specific manufacturing at its remaining locations, with production already relocated and supplies to pharmacies and hospitals guaranteed. The Aschaffenburg site accounted for approximately 10% of the production volume of the Medios Group's German manufacturing facilities. The measure affects 32 employees, for whom Medios is seeking to provide fair compensation.
The decision comes as the business of patient-specific formulations faces sustained margin pressure, particularly due to price regulatory adjustments. Medios is countering these challenges with measures to increase efficiency. In Germany, Medios operates a network of six GMP (Good Manufacturing Practice) manufacturing facilities for patient-specific therapies, which entail mandatory production standards and validated quality management. The Aschaffenburg site had recently been operating at below-average profitability amid declining capacity utilization. Continued economic operation was no longer feasible, and structural renovation work required at the site accelerated the implementation of this decision. The site closure is part of the company's Operational Excellence Program, which aims to sustainably strengthen profitability.
Thomas Meier, CEO of Medios AG, stated, 'With a view to ensuring a reliable supply for our customers and maintaining capacity utilization at all sites, we are now optimizing our successful regional presence strategy and consistently developing it further. With Mannheim and Stuttgart, we have two high-performing Medios sites in southern Germany, ensuring that a reliable supply is maintained.'
Medios AG is a leading provider of Specialty Pharma in Europe, with locations in Germany, the Netherlands, Belgium, and Spain. The company supports key partners in the supply chain with innovative solutions and intelligent services, focusing on pioneering individualized medicine to make the most innovative therapies available to everyone together with pharmacies, specialist practices, and pharmaceutical companies. Medios AG is Germany's first listed specialty pharmaceutical company, with shares listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) and included in the SDAX selection index.
This announcement highlights the ongoing challenges in the pharmaceutical industry, particularly the impact of regulatory price adjustments on manufacturing profitability. By consolidating operations, Medios aims to enhance efficiency and ensure a reliable supply to its customers. The closure of the Aschaffenburg facility underscores the company's commitment to its Operational Excellence Program, which seeks to strengthen profitability in a competitive market. The impact on employees is being addressed with fair compensation, reflecting Medios' focus on responsible corporate practices.
